[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 16, 2002

Guidelines for Treatment of Anthrax

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;288(15):1848-1849. doi:10.1001/jama.288.15.1845

To the Editor: We wish to provide the following factual corrections in response to the article by Dr Inglesby and colleagues1 about anthrax as a biological weapon.

First, Inglesby et al state that there are no US Food and Drug Administration (FDA)–approved postexposure antibiotic regimens following exposure to a Bacillus anthracis aerosol. In fact, on August 30, 2000, the FDA approved ciprofloxacin for use in inhalational anthrax (postexposure) for both adults and children. (Inhalational anthrax postexposure is also referred to as anthrax postexposure prophylaxis [PEP].)